Recently, global wearable device leader Fitbit announced the first quarter of 2016 financial report, sales of 4.8 million, total revenue of 505.4 million US dollars, an increase of 50%. The wearables company’s GAAP (Generally Accepted Accounting Principles) earnings per share for the first quarter were $0.05, and non-GAAP (non-GAAP) earnings per share were $0.1, adjusted for interest, taxes, depreciation, The gain before amortization was $45 million. The main benefit is the wearable products Blaze and Alta Much of the revenue for the first quarter of 2016 was due to the release of Blaze and Alta, with 47% of revenue coming from sales of Blaze and Alta in the late first quarter – one million each sold Pieces. About 40% of Blaze and Alta's active users have the latest and most advanced devices, and 20% return to the Fitbit community to become active users after more than 90 days of inactivity. Fitbit's revenue grew rapidly, with revenue in the first quarter of 2016 increasing by 50% year-on-year. The composition of revenue and major income in the first quarter of recent years is as follows: Fitbit's investment in operations and R&D is also very large. The following is a comparison of operating expenses and changes in R&D personnel: Fitbit cooperates with Chinese e-commerce "Tmall" to explore the Chinese market Tmall will host a brand festival for Fitbit on May 18th to help promote Fitbit's two latest devices, Blaze and Alta. According to foreign media reports: "This cooperation between Fitbit and Tmall is to open up the Chinese market. Tmall's goal is to help Fitbit have 10 million fans in Asia." Enzalutimide Intermediates Cas 179232-29-2 Enzalutamide Intermediate,Enzalutamide Intermediate,Cas 654-70-6 Enzalutamide Intermediates,Cas 143782-23-4 Enzalutamide Intermediates Shijiazhuang Dingmin pharmaceutical Sciences Co.,Ltd , https://www.dingminpharma.com